Drug intelligence / Profile preview

H4R antagonist

Development stage: Preclinical
Lead developer: Griffen
Modality: Small Molecules

Overview

Griffin Discoveries-H4R-small molecule-vestibular disorders refers to a preclinical-stage small molecule program developed by Griffin Discoveries targeting the histamine H4 receptor (H4R). As an H4R antagonist, the compound is designed to modulate the activity of H4 receptors, which are known to be expressed in the vestibular system and play a role in mediating inflammatory and neurotransmitter processes in the inner ear. The primary goal of this therapeutic candidate is the treatment of vestibular disorders, which can manifest as vertigo, dizziness, and balance impairment. The asset is part of Griffin's broader portfolio of histamine receptor ligands derived from their GPCR-focused discovery platform.

Other names: Histamine H4 receptor antagonist

Targets

HRH1 (Histamine H1 Receptor)HRH4 (Histamine H4 receptor)

Beyond the preview

Go deeper on H4R antagonist.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on H4R antagonist.

Explore the full profile